2.7(top 20%)
impact factor
4.0K(top 5%)
papers
40.0K(top 10%)
citations
65(top 10%)
h-index
2.8(top 20%)
impact factor
4.9K
all documents
45.0K
doc citations
90(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Brain health: time matters in multiple sclerosisMultiple Sclerosis and Related Disorders2016280
2Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Multiple Sclerosis and Related Disorders2015275
3Treatment of neuromyelitis optica: Review and recommendationsMultiple Sclerosis and Related Disorders2012217
4High doses of biotin in chronic progressive multiple sclerosis: A pilot studyMultiple Sclerosis and Related Disorders2015191
5Vitamin D and multiple sclerosis: An updateMultiple Sclerosis and Related Disorders2017183
6Classifying PML risk with disease modifying therapiesMultiple Sclerosis and Related Disorders2017181
7MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorderMultiple Sclerosis and Related Disorders2018158
8The COVID-19 pandemic and the use of MS disease-modifying therapiesMultiple Sclerosis and Related Disorders2020153
9COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?Multiple Sclerosis and Related Disorders2020138
10Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosisMultiple Sclerosis and Related Disorders2016133
11Multiple sclerosis following SARS-CoV-2 infectionMultiple Sclerosis and Related Disorders2020127
12B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in IranMultiple Sclerosis and Related Disorders2020123
13People with MS are less physically active than healthy controls but as active as those with other chronic diseases: An updated meta-analysisMultiple Sclerosis and Related Disorders2017118
14Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, SpainMultiple Sclerosis and Related Disorders2020118
15Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trialMultiple Sclerosis and Related Disorders2016117
16Elevated relapse rates in pediatric compared to adult MS persist for at least 6 yearsMultiple Sclerosis and Related Disorders2014116
17The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosisMultiple Sclerosis and Related Disorders2018113
18Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature reviewMultiple Sclerosis and Related Disorders2019111
19Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsMultiple Sclerosis and Related Disorders2020110
20The effect of exercise training in adults with multiple sclerosis with severe mobility disability: A systematic review and future research directionsMultiple Sclerosis and Related Disorders2017109
21Effects of MS disease-modifying therapies on responses to vaccinations: A review.Multiple Sclerosis and Related Disorders2020107
22Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causationMultiple Sclerosis and Related Disorders2017106
23Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findingsMultiple Sclerosis and Related Disorders2014105
24Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosisMultiple Sclerosis and Related Disorders2018105
25The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?Multiple Sclerosis and Related Disorders2018104
26How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanismsMultiple Sclerosis and Related Disorders2020104
27Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose studyMultiple Sclerosis and Related Disorders2014102
28Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimatesMultiple Sclerosis and Related Disorders2014102
29The multiple sclerosis gut microbiota: A systematic reviewMultiple Sclerosis and Related Disorders2020102
30Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering GroupMultiple Sclerosis and Related Disorders2018101
31Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental modelsMultiple Sclerosis and Related Disorders2019101
32Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysisMultiple Sclerosis and Related Disorders2016100
33Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple SclerosisMultiple Sclerosis and Related Disorders201995
34Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosisMultiple Sclerosis and Related Disorders201994
35Review: Patient-reported outcomes in multiple sclerosis careMultiple Sclerosis and Related Disorders201994
36Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysisMultiple Sclerosis and Related Disorders201994
37Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypothesesMultiple Sclerosis and Related Disorders201792
38Incidence of multiple sclerosis misdiagnosis in referrals to two academic centersMultiple Sclerosis and Related Disorders201992
39Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairmentMultiple Sclerosis and Related Disorders202091
40Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disordersMultiple Sclerosis and Related Disorders201789
41Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitisMultiple Sclerosis and Related Disorders201889
42Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims databaseMultiple Sclerosis and Related Disorders201587
43Tumefactive demyelinating lesions: A comprehensive reviewMultiple Sclerosis and Related Disorders201787
44A case of possible atypical demyelinating event of the central nervous system following COVID-19Multiple Sclerosis and Related Disorders202087
45Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering GroupMultiple Sclerosis and Related Disorders201585
46How does cognition relate to employment in multiple sclerosis? A systematic reviewMultiple Sclerosis and Related Disorders201885
47Effectiveness of telerehabilitation interventions in persons with multiple sclerosis: A systematic reviewMultiple Sclerosis and Related Disorders201584
48Optimizing therapy early in multiple sclerosis: An evidence-based viewMultiple Sclerosis and Related Disorders201583
49Virtual reality in multiple sclerosis – A systematic reviewMultiple Sclerosis and Related Disorders201683
50Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United StatesMultiple Sclerosis and Related Disorders202181